MiMedx Group, Inc.
Industry
- Medical Devices
- Biomaterials
- Biotechnology
- Pharmaceuticals
Other Names/Subsidiaries
- SpineMedica Corp., SpineMedica, LLC
Latest on MiMedx Group, Inc.
Biopharma Acquisitions Biopharma merger and acquisition value for the fourth quarter of 2022 reached $35.7bn from 41 transactions, 21 of which had disclosed values. Making up 78% of the Q4 total was A
In a scathing letter to fellow MiMedx Group shareholders, Prescience Point Capital accused the regenerative medicine company’s current board with “failing to effectively convey the potential” of its
Two former top execs at publicly traded wound care company MiMedx Group Inc. have been convicted on securities fraud charges in a New York court, the US Department of Justice announced recently. A j
The market for tissue-engineered skin replacements and wound modulators is expected to reach nearly $1.9bn in 2024, a faster rebound than certain other elective procedures that can be put on hold, acc